Description: RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Home Page: www.rapt.com
RAPT Technical Analysis
561 Eccles Avenue
South San Francisco,
CA
94080
United States
Phone:
650 489 9000
Officers
| Name | Title |
|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | CEO, Pres & Director |
| Mr. Rodney K. B. Young | CFO, Principal Accounting Officer & Sec. |
| Dr. William Ho | Chief Medical Officer |
| Steve Young Ph.D. | VP of Technology |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer |
| Ms. Gwen R. Carscadden | Chief HR Officer |
| Dr. Paul Kassner | Sr. VP of Quantitative & Computational Biology |
| Dr. David Wustrow | Sr. VP of Drug Discovery & Preclinical Devel. |
| Ms. Jennifer Nicholson | Sr. VP of Regulatory Affairs & Quality Assurance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0609 |
| Price-to-Sales TTM: | 266.1551 |
| IPO Date: | 2019-10-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 94 |